| Previous Section | Back to Table of Contents | Lords Hansard Home Page |
Fire and Rescue National Framework 2005–06
The Minister of State, Office of the Deputy Prime Minister (Lord Rooker): My right honourable friend the Minister for Local and Regional Government, Mr Nick Raynsford, has made the following Written Ministerial Statement.
Today the Office of the Deputy Prime Minister is publishing the 2005–06 Fire and Rescue National Framework.
The Government remain committed to reduce the number of fire deaths and deliberate fires. The Office of the Deputy Prime Minister's fire public service agreement target commits us to achieving long-term reductions in fire deaths and arson, including in the worst off areas. The Government also recognise the importance of working closely with fire and rescue authorities and their staff in order to achieve these goals.
The Fire and Rescue National Framework sets out the strategy for meeting the Government's objectives and delivering an improved service that achieves better value for money for the communities it serves.
6 Dec 2004 : Column WS48
At the request of fire and rescue authorities we agreed to publish the 2005–06 national framework in time to inform authorities' budget setting processes. The 2005–06 national framework reflects progress that has been, made since the publication of the 2004–05 national framework in July 2004 and reflects comments we have received in response to our consultation exercise. We have carefully considered all responses and have reflected them in the national framework where appropriate. The Government's full response to the comments is published on the ODPM website.
The national framework is a forward looking document. Fire and rescue authorities will soon begin the process of comprehensive performance assessment. Fire CPA will provide a robust assessment of progress by the service since publication of the White Paper and a firm basis for further improvement.
The 2005–06 national framework has effect under Section 21(6) of the Fire and Rescue Services Act 2004 as a revision, which appears to the Secretary of State to be significant, of the 2004–05 national framework.
Copies of the 2005–06 national framework will be made available in the Libraries of both Houses.
Bosnia and Herzegovina: Export Licence Application
The Minister of State, Foreign and Commonwealth Office (Baroness Symons of Vernham Dean): In September 2004 the Government issued a licence for the export of ballistic body armour vests to the Ministry of Security in Bosnia and Herzegovina. The Ministry of Security requires the vests for the State Information and Protection Agency (SIPA). SIPA is responsible for, inter alia, diplomatic protection, which includes the British Embassy in Sarajevo as well as the missions of EU partners and other allies; tackling organised crime; and investigating war crimes.
An EU arms embargo has been in place against Bosnia and Herzegovina since 1996. The purpose of the embargo was to aid the establishment of peace and stability for the people of the region, taking into account in particular the need to ensure the safety of international troops and civilian personnel deployed. The embargo was amended in 1999 to exclude demining equipment and the transfer of small arms to the police.
We fully support the EU embargo. However, we are, in limited circumstances, prepared to make exemptions where denying an export would frustrate the purposes of the embargo. The UK has been active in encouraging Bosnia and Herzegovina to take greater responsibility for maintaining the rule of law and strengthening civilian policing. I am confident that granting this exception is fully consistent with this responsible approach of supporting the development of civilian policing while respecting the aims of the embargo.
6 Dec 2004 : Column WS49
Delivering Justice, Rights and Democracy: DCA Strategy 2004–09
The Secretary of State for Constitutional Affairs and Lord Chancellor (Lord Falconer of Thoroton): I am today publishing DCA'S strategy for the next five years. This explains how we intend to reform and modernise the justice system and constitution so that they are transparent, accountable and responsive to the needs of the public. An overview of the strategy and the detailed strategy itself are both available on the DCA website (www.dca.gov.uk), and I shall also be placing copies in the Libraries of both Houses.
Selective Serotonin Re-uptake Inhibitors
The Parliamentary Under-Secretary of State, Department of Health (Lord Warner): Following interest in both Houses about the issues surrounding the safety of selective serotonin re-uptake inhibitors (SSRIs), this Statement informs the House of the completion of the United Kingdom review of SSRIs and the publication today of the report. The Committee on Safety of Medicines (CSM) expert working group has now delivered comprehensive advice on the use of these drugs in children, young people and adults following a thorough review of all the evidence available. This gives parents, patients and those who treat depressive illnesses the information they need to make informed decisions about treatment of these potentially devastating conditions.
In 2003 an expert working group of the CSM was set up to consider further the safety of SSRIs, with particular reference to suicidal behaviour and withdrawal reactions. The expert group has examined all the evidence available from a wide range of sources, including a specific objective to listen to the patient viewpoint. The expert group has already reached conclusions on the use of SSRIs in children and the Government have published its findings. This latest report focuses on the use of SSRIs in adults. The work of this group is now complete and a comprehensive account of this work is being published today. In short, it concludes that:
there should be strengthened warnings on coming off SSRIs at the end of a course of treatment and how to minimise the risk of experiencing a withdrawal reaction;
there should be specific advice on using the recommended dose of the SSRI because for the
- majority of SSRIs in depression, clinical trial data do not show an additional benefit above the lowest recommended dose;
there should be clearer advice on what is known about the risk of suicide and suicidal behaviour—while clinical trial data cannot rule out a modest increase in the risk compared to placebo, there is now good evidence from large population studies that there is no clear increase in the risk of suicide in relation to SSRIs compared to other antidepressants;
there is no clear evidence of an increased risk of self-harm and suicidal thoughts in young adults of 18 years or over. But individuals mature at different rates and young adults are at a higher background risk of suicidal behaviour than older adults, so as a precautionary measure young adults treated with SSRIs should be closely monitored. The expert group also recommended that in further research on the safety and efficacy of SSRIs young adults should be assessed separately.
The CSM has also recommended that treatment with venlafaxine (Efexor) should only be initiated by specialists and that there should be in place arrangements for ongoing supervision of the patient.
The report includes the key evidence on which the advice of the expert working group is based, including summaries of clinical trials submitted by companies at the MHRA's request. This unusual step demonstrates the MHRA's commitment to being as open as possible in drug regulation.
The report of the expert group is being published alongside guidelines from the National Institute for Clinical Excellence (NICE) on depression and anxiety. In this way, the new advice of CSM can feed directly into clinical practice. Copies of the expert group's report and the NICE guidelines have been placed in the Library.
Communications to patients and prescribers are taking place today and copies of these materials have also been placed in the Library. SSRIs are an important group of medicines, which help patients who suffer depressive illness. The health benefits of SSRIs in adults are still considered to outweigh the risk of adverse drug reactions. Patients currently taking venlafaxine should not stop taking their medicine but should consult their doctor for advice on treatment as should patients taking other SSRIs who are experiencing any side effects or are concerned about their treatment.
6 Dec 2004 : Column WS49
| Next Section | Back to Table of Contents | Lords Hansard Home Page |